(FM) Inmunología
Departamento académico
Bruno Carlos
Sangro Gómez-Acebo
Catedrático de Universidad
Publicaciones en las que colabora con Bruno Carlos Sangro Gómez-Acebo (33)
2024
-
Nivolumab in sorafenib-naive and sorafenib-experienced patients with advanced hepatocellular carcinoma: 5-year follow-up from CheckMate 040
Annals of Oncology, Vol. 35, Núm. 4, pp. 381-391
-
Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040
Annals of Oncology, Vol. 35, Núm. 6, pp. 537-548
2023
-
Synergistic effects of combined immunotherapy strategies in a model of multifocal hepatocellular carcinoma
Cell Reports Medicine, Vol. 4, Núm. 4
2022
-
Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial
The Lancet Oncology, Vol. 23, Núm. 1, pp. 77-90
2021
-
Advances in immunotherapy for hepatocellular carcinoma
Nature Reviews Gastroenterology and Hepatology, Vol. 18, Núm. 8, pp. 525-543
-
CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis
Journal of Hepatology, Vol. 75, Núm. 3, pp. 600-609
-
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma
Journal for ImmunoTherapy of Cancer, Vol. 9, Núm. 9
2020
-
Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma
Journal of Hepatology, Vol. 73, Núm. 6, pp. 1460-1469
-
Efficacy and Safety of Nivolumab plus Ipilimumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib: The CheckMate 040 Randomized Clinical Trial
JAMA Oncology
2018
-
Immunotherapy of hepatocellular carcinoma: Facts and hopes
Clinical Cancer Research, Vol. 24, Núm. 7, pp. 1518-1524
2017
-
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
The Lancet, Vol. 389, Núm. 10088, pp. 2492-2502
2015
-
Immune monitoring of immunosuppression withdrawal of liver transplant recipients
Transplant Immunology, Vol. 33, Núm. 2, pp. 110-116
-
Immunological landscape and immunotherapy of hepatocellular carcinoma
Nature Reviews Gastroenterology and Hepatology, Vol. 12, Núm. 12, pp. 681-700
2014
-
Serum interleukin-8 reflects tumor burden and treatment response across malignancies of multiple tissue origins
Clinical Cancer Research, Vol. 20, Núm. 22, pp. 5697-5707
2013
-
A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C
Journal of Hepatology, Vol. 59, Núm. 1, pp. 81-88
-
Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model
Clinical Cancer Research, Vol. 19, Núm. 22, pp. 6151-6162
-
Trial of complete weaning from immunosuppression for liver transplant recipients: Factors predictive of tolerance
Liver Transplantation, Vol. 19, Núm. 9, pp. 937-944
2011
-
Pilot clinical trial of type 1 dendritic cells loaded with autologous tumor lysates combined with GM-CSF, pegylated IFN, and cyclophosphamide for metastatic cancer patients
Journal of Immunology, Vol. 187, Núm. 11, pp. 6130-6142
-
Synergistic effects of CTLA-4 blockade with tremelimumab and elimination of regulatory T lymphocytes in vitro and in vivo
International Journal of Cancer, Vol. 129, Núm. 2, pp. 374-386
2009
-
Clinical development of combination strategies in immunotherapy: Are we ready for more than one investigational product in an early clinical trial?
Immunotherapy, Vol. 1, Núm. 5, pp. 845-853